Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Total Current Liabilities (2016 - 2025)

Amphastar Pharmaceuticals has reported Total Current Liabilities over the past 13 years, most recently at $158.2 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $158.2 million for Q4 2025, down 8.98% from a year ago — trailing twelve months through Dec 2025 was $158.2 million (down 8.98% YoY), and the annual figure for FY2025 was $158.2 million, down 8.98%.
  • Total Current Liabilities for Q4 2025 was $158.2 million at Amphastar Pharmaceuticals, down from $205.2 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for AMPH hit a ceiling of $258.0 million in Q3 2023 and a floor of $94.9 million in Q4 2022.
  • Median Total Current Liabilities over the past 5 years was $147.6 million (2024), compared with a mean of $158.6 million.
  • Biggest five-year swings in Total Current Liabilities: soared 152.43% in 2023 and later crashed 45.49% in 2024.
  • Amphastar Pharmaceuticals' Total Current Liabilities stood at $103.8 million in 2021, then fell by 8.62% to $94.9 million in 2022, then soared by 137.62% to $225.4 million in 2023, then dropped by 22.91% to $173.8 million in 2024, then fell by 8.98% to $158.2 million in 2025.
  • The last three reported values for Total Current Liabilities were $158.2 million (Q4 2025), $205.2 million (Q3 2025), and $176.4 million (Q2 2025) per Business Quant data.